Chemical industry – Page 105
-
Business
Business roundup: October 2010
Sanofi bid too low says Genzyme Source: © SANOFI AVENTIS Christopher Viehbacher: ’offer provides immediate and certain value Sanofi-Aventis is not being bashful about its designs on Genzyme any longer. The French pharma giant has offered $69 (£45) per share in an all-cash bid that values the ...
-
Opinion
How much selectivity do you want?
Derek Lowe considers the quandaries of living in the age of the kinase
-
Business
Business roundup: September 2010
Falling sales at Johnson & Johnson ’s (J&J) consumer healthcare division have hurt the pharma giant’s US sales, which fell 2.8 per cent compared to the same period last year. Globally, sales for the company’s consumer goods division fell 5.4 per cent to $3.6 billion (£2.3 billion) - ...
-
Opinion
Missing methods
Derek Lowe reminisces about lost laboratory techniques and wonders which will be next to go
-
Business
Business roundup: August 2010
Bittersweet victory for GSK’s Avandia GlaxoSmithKline (GSK) has received a muted ’thumbs up’ from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration (FDA) will allow the UK-based pharma giant to continue selling the drug in ...
-
Business
Business roundup: July 2010
Eight convicted for Bhopal disaster More than 25 years after one of the worst industrial accidents in living memory, the Magistrate’s court in Bhopal, India, has convicted eight former Union Carbide employees of ’causing death by criminal negligence’. The eight convicted include Keshub Mahindra, former chairman of the Indian subsidiary ...
-
Opinion
If something can’t go on, then it won’t
Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
-
Business
Business roundup: June 2010
The green shoots of a chemical spring Recent data seem to suggest that the chemical industries have weathered the worst of the economic storm, at least for now. Cefic, the European Chemical Industry Council, has updated its Chemical Trends report which shows that the European chemicals industry has now ...
-
OpinionDeath by assay result
Derek Lowe wonders whether tagging molecules with fluorescent labels for assay is like tracking the members of a shoal of fish by tying each one to a whale
-
Business
Business roundup: May 2010
Comparative effectiveness With the US coming to terms with the biggest changes to its healthcare system in 60 years, a measure hidden deep within the 2400-page law has come to light - that of comparative effectiveness. The measure will create an institute funded by around $500 million (£335 million) a ...
-
Opinion
How to be an organised scientist
Derek Lowe waxes lyrical about the joys of the electronic lab notebook
-
Business
Business roundup: April 2010
Merck joins the cost-cutting crowd Following its $41 billion (£27 billion) merger with Schering-Plough, US drug giant Merck & Co. has announced a ’merger restructuring plan’ that in its first phase will see 17,500 jobs cut. At the time of the merger announcement, the company said it aimed to shave ...
-
Business
Business roundup: March 2010
Air Products makes hostile bid for Airgas Air Products has launched a $7 billion (£4.47 billion) hostile takeover bid for rival gas supplier Airgas to gain access to the US bottled gas market. If shareholders take up the $60 a share bid, the combined company would become the largest industrial ...
-
Opinion
Papers vs patents
Derek Lowe wonders whether peer-reviewed papers or patents are more reliable
-
Business
Business roundup: February 2010
Haiti’s helpers The horrendous magnitude 7.0 earthquake that hit Haiti has prompted many companies to provide what assistance they can. The earthquake has destroyed roads and buildings and claimed thousands of lives - the Red Cross has estimated that at least 50,000 people have lost their lives to the quake ...
-
Business
Business roundup: January 2010
Bayer to reduce cost of chlorine production German chemicals giant Bayer is commercialising a new way of making chlorine that it says uses 30 per cent less energy than current production methods. Better still, the company plans to make it possible to retrofit the technology to existing plants. Around ...
-
Opinion
The sincerest form of flattery
Is the pharmaceutical industry churning out copycat versions of existing therapies? Derek Lowe dispels a few myths about 'me-too' drugs